Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...
Zacks.com on MSN13h
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowAbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
17h
Neurologist Jason Aldred helped conduct trials for the device in Spokane through his work at Selkirk Neurology, where he ...
Toby Kent of AbbVie UK highlights how the forthcoming NHS 10-year plan is a crucial opportunity to set out a vision for ...
HealthDay on MSN20h
FDA Approves Vyalev for Advanced Parkinson DiseaseThe U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...
Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback